Inhibitors of the IL-6/IL-6R system have been approved by the FDA for rheumatoid arthritis and Castleman’s disease: Tocilizumab (Actemra) and Sarilumab (Kevzara) target the membrane and soluble IL-6 receptors, Siltuximab (Sylvant) targets IL-6 (Prairie et al, 2021). The gene discussed is IL6; the disease is Castleman disease.